Nosisa Sipambo
Overview
Explore the profile of Nosisa Sipambo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dawood H, Richards L, Lutchminarain K, Parker A, Wattrus C, Sipambo N, et al.
South Afr J HIV Med
. 2024 Nov;
25(1):1657.
PMID: 39507465
No abstract available.
2.
Zaniewski E, Skrivankova V, Brazier E, Avihingsanon A, Cardoso S, Cesar C, et al.
AIDS
. 2024 Sep;
38(15):2073-2085.
PMID: 39236112
Objective: We studied the transition to dolutegravir-containing antiretroviral therapy (ART) at HIV treatment clinics within the International epidemiology Databases to Evaluate AIDS (IeDEA). Design: Site-level survey conducted in 2020-2021 among...
3.
Sorour G, Sipambo N, Archary M
South Afr J HIV Med
. 2023 Dec;
24(1):1506.
PMID: 38089886
No abstract available.
4.
de Waal R, Rabie H, Technau K, Eley B, Sipambo N, Cotton M, et al.
Antivir Ther
. 2023 Apr;
28(2):13596535231168480.
PMID: 37038365
Background: WHO guidelines recommend abacavir in first-line antiretroviral treatment for children and neonates. However, there is no approved dose <3 months of age, and data in neonates are limited. Methods:...
5.
Patten G, Sipambo N, Technau K, Euvrard J, Ford N, Davies M
J Acquir Immune Defic Syndr
. 2023 Feb;
92(4):273-280.
PMID: 36729553
Background: Among children in Southern Africa severe immune suppression (SIS) has declined, but most continue to initiate antiretroviral therapy (ART) with SIS. Setting: Using data from South Africa, we describe...
6.
Nyakato P, Schomaker M, Fatti G, Tanser F, Euvrard J, Sipambo N, et al.
J Int AIDS Soc
. 2022 Jan;
25(1):e25870.
PMID: 35032096
Introduction: Older adolescents aged 15-19 years continue to have high rates of loss to follow up (LTFU), and high rates of virologic non-suppression (VNS) compared to younger adolescents and adults....
7.
Archary M, Van Zyl R, Sipambo N, Sorour G
South Afr J HIV Med
. 2021 Oct;
22(1):1278.
PMID: 34691769
While the progress towards reaching the UNAIDS 95-95-95 targets in South African adults seems promising, the progress in the paediatric population is lagging far behind; only 79% percent of children...
8.
Moore D, Baillie V, Mudau A, Wadula J, Adams T, Mangera S, et al.
Pediatr Infect Dis J
. 2021 Aug;
40(9S):S69-S78.
PMID: 34448746
Background: HIV-1 infection predisposes to an increased burden of pneumonia caused by community-acquired and opportunistic pathogens. Methods: Within the context of the Pneumonia Etiology Research for Child Health case-control study...
9.
Nyakato P, Schomaker M, Sipambo N, Technau K, Fatti G, Rabie H, et al.
AIDS
. 2021 Jan;
35(6):971-978.
PMID: 33492836
Background And Objectives: Adolescents living with perinatally acquired HIV (ALPHIV) on antiretroviral therapy (ART) have been noted to have poorer adherence, retention and virologic control compared to adolescents with non-perinatally...
10.
Pillay T, Cornell M, Fox M, Euvrard J, Fatti G, Technau K, et al.
Antivir Ther
. 2020 Sep;
25(5):257-266.
PMID: 32960187
Background: Viral suppression in patients on antiretroviral treatment (ART) is critical to reducing HIV transmission and HIV-related mortality. Although many studies have evaluated factors associated with viral suppression, few have...